One way to look at Friday's fins is to look at what

New Post Public Reply Private Reply Replies (3) Message Board
reindeer830 mikeyt1818 #2906
407
One way to look at Friday's fins is to look at what happened to the pps when we reported last quarter's fins.

After a very good run up in pps the 1st week of Sept, we closed at $.0092 on Fri Sept 8th. The week of 11th to 15th - prior to fins - saw a nice run to $.0123 for a 33.7% gain. Monday, the 18th (1st trading day after fins) saw an additional increase of 38.2% to close at $.0170. This meant for the 5 days prior to fins and 1 day after fins release saw a cumulative gain of $.0078 or 84.8%.

For many reasons - some known & some unknown - pps has taken a beating over the last several weeks. So, we closed last Friday (Dec 8th) at $.0053 which is/was a big drop from the $.0092 we had on Sep 8th. Applying the actual % growth we realized when last quarter fins were reported on the current pps gets us to $.0071 this Fri (the 15th) and then - with a similar increase that we saw on the first trading day after fins last Q could get us to $.0098 next Monday the 18th. Basic trending. But whats different this quarter. Are revenues the same or better? Reduction in shares? More sales/contracts signed? Debt paid? Closer to name change? More and bigger potential revenue drivers identified? (I think Dubai is new, but, its hard to keep up with SB) Something really, really big could happen here!

Truthfully, before the recent decline in pps, most expected the pps after record 4Q revenue to be much higher. I did! I misjudged the impact debt repayment would have because I didn't include the "profit taking" that started when the debt repayment started to have an impact. Realistically, there were a lot of shares bought at $.001 and in the trips. There was a lot of profit to be taken and people took it. Throw in some impact from the determined bunch of bashers and we had a trifecta driving the pps down. And our reported sales that had supported the steady growth in the pps were now challenged on several fronts. We had delays on several fronts. We had a decreasing pps!

But, we still had our business fundamentals and Steve and some rather exciting possibilities . Some potential contracts in the future cold easily be bigger that most of our sales in 2017 combined. But, big deals take more time than the little ones.

I'll close by saying I feel great about seeing an epic run between now and mid Feb that will serve as a great start for a fabulous 2018. We should get FINRA's blessing on the Hexagon name change soon after approval by CO SOS. That could launch an announcement of several deals - big & small - in the Hexagon name. We will see better fins than the 3Q fins that caused the pps to run high and fast. We may start to see the potential revenue impacts from new revenue streams in 2018. Later but in early 2018, we could see the huge news that Steve has promised. I've never suggested a pps "in dollars" but I did say I expected to see nickels. I still see nickels short term and that's nickels with an "s". Go ONCI

On4 Communications (ONCI) Stock Research Links

ONCI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 29

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 28

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 24

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 35

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 30

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 20

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Endava Investors: Legal Action Could Recover Your Losses

Updated Category News Views 87

Endava got tangled in a class action lawsuit over securities fraud back in 2024. Investors were already feeling the squeeze as whispers about declining demand for its services echoed through the trading floor. You know how it goes—when rumors hit, shares take a dive faster than you can blink. Class Action Reality: Who Gets to Play? The lawsuit targeted shareholders who...

Continue Reading
New Mortgage Ratings Assigned to Deephaven Trust Portfolio

Updated Category News Views 177

Introduction to Deephaven Residential Mortgage Trust 2024-1 In an important development within the non-prime mortgage market, KBRA has recently assigned preliminary ratings to eight classes of mortgage-backed notes from Deephaven Residential Mortgage Trust 2024-1 (DRMT 2024-1). This $514.6 million transaction comprises a unique pool of 1,330 residential mortgages,...

Continue Reading
Meta Platforms Declares Cash Dividend for Shareholders

Updated Category News Views 325

Quarterly Cash Dividend Announcement from Meta Platforms The board of directors of Meta Platforms, Inc. (NASDAQ: META) has recently declared a quarterly cash dividend of $0.525 per share, benefitting shareholders holding both Class A and Class B common stock. This dividend reflects the company's ongoing commitment to returning value to its shareholders. Dividend Payment...

Continue Reading
Campine Expects Strong Financial Upsurge in 2024 Performance

Updated Category News Views 125

Campine NV Forecasts Impressive Growth in 2024 Campine NV, a well-known name in the metals recycling and specialty chemicals sector, is gearing up for a promising financial year ahead. The company has recently indicated that it anticipates higher profits in 2024, thanks to favorable market conditions. Projected Revenue Growth for 2024 According to Campine's expectations,...

Continue Reading
Thumzup Media's Strategic Investment in Dogecoin Ahead of ETFs

Updated Category News Views 147

Thumzup Media's Strategic Move into Dogecoin Thumzup Media Corporation (Nasdaq: TZUP) has made headlines with its latest purchase of Dogecoin, securing around 7.5 million tokens valued at approximately $2 million. This significant acquisition marks the company's first open-market investment in Dogecoin, reflecting a strong belief in the digital currency's potential for...

Continue Reading